Medicare, Eli Lilly and sleep apnea
Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...
Scorpion’s drug candidate inhibits a mutation that is a major driver of breast, gynaecological and head and neck cancers ...
It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...
Eli Lilly will seek to have Mounjaro listed on the scheme this year. If successful, it would mean taxpayer subsidies for the ...
Dual- and triple-agonist GLP-1s appear to achieve greater weight loss in an overview of clinical trials of approved and ...
The round is one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.
Eli Lilly's stock has been a strong winner over the past few years, powered by its portfolio of glucagon-like peptide-1 ...
"Coverage for these weight-loss drugs has significant cost implications for employers, as a previous KFF analysis estimated ...
Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback